Skip to main content
Premium Trial:

Request an Annual Quote

RXi Regains Nasdaq Listing

Premium

RXi Pharmaceuticals announced this month that its stock has once again begun trading on the Nasdaq stock market.

"Listing on Nasdaq will help us gain access to a broader institutional investment community and to provide greater liquidity for our shareholders," RXi President and CEO Geert Cauwenbergh said in a statement.

RXi had previously traded on the Nasdaq but lost its listing when it merged with Apthera in 2011. The new company changed its name to Galena, took RXi’s stock listing, and made RXi a subsidiary. RXi was later spun out as a publicly traded independent company again, but traded on the over-the-counter bulletin board.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.